Charles River Laboratories International (CRL) traded higher today, with the move appearing driven by incremental bullishness in analyst commentary and price-target revisions circulating this week rather than a new company press release this morning. Recent analyst updates include Barclays maintaining a Buy stance with a $210 price target (noted in the last few days) and a recent JPMorgan price-target increase to $190 while keeping a Neutral rating, which helped re-anchor investor expectations after a volatile reset in the name. (investing.com)

The stock’s rebound is also being interpreted through the lens of the company’s latest full-year update: on February 18, 2026, Charles River reported Q4 and full-year 2025 results and issued 2026 guidance. Management’s outlook called for non-GAAP EPS of $10.70–$11.20, with the narrative centered on protecting and expanding margins through cost actions even as organic revenue is expected to be roughly flat to slightly down. (sec.gov)

Investors will be monitoring for evidence that bookings and study-start activity improve enough to support the second-half recovery thesis embedded in many models, and for additional portfolio actions tied to the company’s strategic review and capital allocation priorities (including the previously authorized share repurchase capacity). Near-term, further analyst revisions and any business-update disclosures tied to strategic actions remain the most likely catalysts for outsized day-to-day moves. (ir.criver.com)